文献速递生殖医学

冻融囊胚激素替代周期中肌注黄体酮添加不改善持续妊娠率

Addition of intramuscular progesterone to vaginal progesterone in hormone replacement therapy in vitrified-warmed blastocyst transfer cycles.
PubMed 文献 · Reprod Biomed Online · 2020-02-15

一项单中心回顾性纵向队列研究纳入475个冻融囊胚激素替代周期,比较仅阴道黄体酮(143例)与每三天加用肌注黄体酮(332例)的持续妊娠率(OPR)。两组OPR分别为48.3%和51.8%(P=0.477),血清黄体酮水平及给药类型均非OPR独立预测因素,各百分位亚组OPR相似。结论:每三天肌注黄体酮添加总体上不提高OPR。

要点

  • 每三天肌注黄体酮添加与仅阴道黄体酮的OPR无显著差异(48.3% vs 51.8%,P=0.477)。
  • 血清黄体酮水平及黄体酮给药类型均非OPR的独立预测因素。
  • 按血清黄体酮百分位分层后,两组各亚组OPR相似。

核心结论

  • 每三天肌注黄体酮添加总体上不提高冻融囊胚激素替代周期的持续妊娠率。

研究设计与样本

  • 单中心回顾性纵向队列研究,纳入475个连续的第5–6天冻融囊胚激素替代周期。
  • 仅阴道黄体酮组143例,每三天加用肌注黄体酮组332例。
  • 于黄体酮给药第6天、冻融胚胎移植前即刻测量循环黄体酮水平,主要结局为持续妊娠率(OPR)。

主要发现

  • 仅阴道黄体酮组与肌注黄体酮添加组的OPR分别为48.3%和51.8%(P=0.477)。
  • 循环黄体酮水平及黄体酮给药类型均非OPR的独立预测因素。
  • 按血清黄体酮百分位(<10%、10–49%、50–90%、>90%)分层,以50–90%为参照,两组各百分位亚组OPR相似。

临床怎么用

  • 在激素替代冻融囊胚移植周期中,无需常规每三天加用肌注黄体酮以改善持续妊娠率。

局限性

  • 研究为单中心回顾性队列设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does intramuscular progesterone supplementation ensure ongoing pregnancy rates (OPR) comparable with vaginal progesterone only in hormone replacement therapy cycles for vitrified-warmed embryo transfer; and is there a window of serum progesterone concentration out of which reproductive outcomes may be negatively affected? DESIGN: Retrospective longitudinal cohort study carried out at a single IVF clinic. In total, 475 consecutive, day-5 to day-6 vitrified-warmed embryo transfer cycles using hormone replacement therapy regimen were included. Vaginal progesterone only was given to 143 patients; supplementation of vaginal progesterone only with intramuscular progesterone supplementation every third day was given to 332 patients. On the sixth day of progesterone administration, immediately before frozen-thawed embryo transfer, circulating progesterone levels were measured. Main outcome measure was OPR. RESULTS: The baseline demographic features and embryological data of the vaginal progesterone only and intramuscular progesterone supplementation groups were comparable. The OPR were 48.3% and 51.8%, respectively (P = 0.477). Neither the circulating progesterone level nor the type of progesterone administration were independent predictors of OPR. The effect of serum progesterone levels on OPR was evaluated by percentiles (<10%, 10-49%, 50-90% and >90%), taking 50-90% as the reference sub-group. All percentiles in the intramuscular progesterone supplementation group and in the vaginal progesterone only group had similar OPR. CONCLUSIONS: Intramuscular progesterone supplementation every third day, overall, does not enhance OPR compared with vaginal progesterone only.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Polat M, Mumusoglu S, Bozdag G, et al. Addition of intramuscular progesterone to vaginal progesterone in hormone replacement therapy in vitrified-warmed blastocyst transfer cycles. Reprod Biomed Online. 2020. PMID: 32362573. doi:10.1016/j.rbmo.2020.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。